The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
doravirine, islatravir
2 marketed package NDCs · 1 active manufacturer
Same drug class
Other molecules FDA puts in Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- emtricitabine, rilpivirine and tenofovir disoproxil fumarate· 1 maker
- emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide· 1 maker
- emtricitabine, rilpivirine, tenofovir disoproxil fumarate· 1 maker
- dolutegravir sodium and rilpivirine hydrochloride· 2 makers
- doravirine, lamivudine, and tenofovir disoproxil fumarate· 2 makers
- efavirenz, lamivudine and tenofovir disoproxil fumarate· 2 makers
- emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate· 2 makers
- doravirine· 5 makers
- efavirenz, emtricitabine and tenofovir disoproxil fumarate· 7 makers
- rilpivirine· 7 makers
- rilpivirine hydrochloride· 8 makers
- nevirapine· 10 makers
Common questions
- Is Doravirine, islatravir in shortage right now?
- No. FDA does not currently list Doravirine, islatravir in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Doravirine, islatravir?
- 1 company has marketed Doravirine, islatravir in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.